Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.75 |
| ▸ | POLA1 | P09884 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.62 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.58 |
| ▸ | VDR | P11473 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | OSBP | P22059 | 1/20 | 0.54 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266898 | 1.00 | CDC25A (0.75) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL12695628 | 1.00 | CDC25A (0.75) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL875595 | 0.95 | CDC25A (0.76) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL17123434 | 0.95 | CDC25A (0.76) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL19009189 | 0.95 | CDC25A (0.76) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL19009194 | 0.91 | CDC25A (0.73) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL2508826 | 0.90 | CDC25A (0.72) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL4315337 | 0.90 | CDC25A (0.72) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL2508823 | 0.90 | CDC25A (0.72) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL12086538 | 0.90 | CDC25A (0.74) | CDC25APOLA1CYP2D6CYP2C19INPP5D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569706-B2 | Glycerol derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20050208015-A1 | Glycerol derivative | TECNO NETWORK SHIKOKU CO., LTD (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1550651-A1 | GLYCEROL DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050208015-A1 | Glycerol derivative | GK, GLS, GLS2 | CDC25A 1285/4885POLA1 2312/4885CYP2D6 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.